Publication

Accueil/Publication

Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine

Poster EUROoCS H. Le et al. EUROoCS 2020 Download the [...]

Par |2020-07-10T17:23:17+02:00juillet 8th, 2020|Publication|Commentaires fermés sur Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
Lire la suite

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster [...]

Par |2020-06-23T11:26:39+02:00juin 22nd, 2020|BT-001, Invir.IO, Publication|Commentaires fermés sur BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Lire la suite

Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download [...]

Par |2020-03-22T17:47:45+01:00novembre 8th, 2019|Publication, TG1050|Commentaires fermés sur Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Lire la suite

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane. M. Harper, et al. Gynecologic Oncology, April 2019 - [...]

Par |2019-07-01T11:48:29+02:00avril 18th, 2019|Publication, TG4001|Commentaires fermés sur The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Lire la suite

Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice

Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November [...]

Par |2019-07-01T15:33:42+02:00novembre 30th, 2018|Publication, TG1050|Commentaires fermés sur Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Lire la suite
Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166 67405 Illkirch Graffenstaden Cedex - France | Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11
© 2019 Transgene - All rights reserved
Mentions légales - Crédits
Go to Top